Source comparison
How to Use Peptides for Ligament Repair: Protocol Comparison
Dosing frequency Daily (once per day) Twice weekly (every 3–4 days) BPC-157 daily + TB-500 twice weekly Combined protocols are supported in animal models but lack human RCT data. Use with physician oversight Standard research dose 250–500 mcg/day subcutaneous
This comparison does not assign a generated winner or score.
- Dosing frequency
- Daily (once per day)
- Twice weekly (every 3–4 days)
- BPC-157 daily + TB-500 twice weekly
- Combined protocols are supported in animal models but lack human RCT data. Use with physician oversight
- Standard research dose
- 250–500 mcg/day subcutaneous
- 2–5 mg per injection
- BPC-157 250 mcg/day + TB-500 2 mg twice weekly
- Dose escalation above these ranges shows no additional benefit in published studies
- Injection site
- Within 5–10 cm of injury
- Proximal to surgical site
- Alternating sites around injury
- Local administration produces 3–5× higher tissue concentrations than distant IM injection
- Protocol duration
- 4–8 weeks
- 8–12 weeks post-op
- 8–12 weeks minimum
- Stopping before 6 weeks eliminates remodeling-phase benefit
- Storage requirement
- 2–8°C (refrigerated) after reconstitution
- Both refrigerated; separate vials
- Temperature excursions above 8°C denature protein structure irreversibly
- Expected recovery reduction
- 30–40% faster vs natural healing
- 25–35% faster collagen remodeling
- 40–50% faster in animal tendinopathy models
- Human clinical data remains limited. Extrapolate cautiously from animal research